THE CIRCULATORY REGULATION OF TPA AND UPA SECRETION, CLEARANCE, AND INHIBITION DURING EXERCISE AND DURING THE INFUSION OF ISOPROTERENOL ANDPHENYLEPHRINE

Citation
Wl. Chandler et al., THE CIRCULATORY REGULATION OF TPA AND UPA SECRETION, CLEARANCE, AND INHIBITION DURING EXERCISE AND DURING THE INFUSION OF ISOPROTERENOL ANDPHENYLEPHRINE, Circulation, 92(10), 1995, pp. 2984-2994
Citations number
75
Categorie Soggetti
Cardiac & Cardiovascular System",Hematology
Journal title
ISSN journal
00097322
Volume
92
Issue
10
Year of publication
1995
Pages
2984 - 2994
Database
ISI
SICI code
0009-7322(1995)92:10<2984:TCROTA>2.0.ZU;2-Q
Abstract
Background Exercise to exhaustion and infusions of isoproterenol and p henylephrine were used to study interactions between plasminogen activ ator regulation and the control of regional blood flow in 10 healthy m ales. Methods and Results Experimental measurements of cardiac output, heart rate, tissue plasminogen activator (TPA), urokinase plasminogen activator (UPA), plasminogen activator inhibitor (PAI-1), C1-inhibito r, and TPA/C1-inhibitor complex during the infusions and exercise were used to develop a comprehensive fluid-phase model of the circulatory regulation of fibrinolysis. alpha- and beta-adrenergic agonists increa sed TPA and UPA in plasma by different mechanisms: Phenylephrine decre ased hepatic blood flow and thus clearance while isoproterenol stimula ted increased secretion of TPA and UPA. Exercise to exhaustion increas ed TPA and UPA through a combination of increased secretion and decrea sed clearance. The time course of UPA and TPA release were similar, bu t tile magnitude of their secretion responses differed. In vivo, C1-in hibitor bound to TPA at a rate of 553 mol(-1) . s(-1). C1-inhibitor co ntributed equally with PAI-1 to TPA inhibition when active PAI-1 level s were low (20 to 50 pmo/L) but was less important when active PAI-1 l evels were high. Conclusions We conclude that secretion. inhibition, c learance, and regional blood flow effects must all be taken into accou nt when evaluating changes in plasminogen activator levels.